Persistent Bacteremia from

Louie Mar Gangcuangco, Patricia Clark, Cynthia Stewart, Goran Miljkovic, Zane K Saul

Open access · goldAbstract read

In one paragraph

Article in Case reports in infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it

0cells of the map it votes in

7citing papers in PubMed

1.0field-weighted citation impact, top 26% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

Prevalence ofFrontiers in microbiology · 2021
Article
Ceftolozane-tazobactam- and ceftazidime-avibactam-resistantAccess microbiology · 2020
Article
Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.The Journal of antimicrobial chemotherapy · 2019
Article
A 2.5-years within-patient evolution of aAntimicrobial agents and chemotherapy · 2019
Article
Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.mBio · 2018
Article
Multicenter Evaluation of the Etest Gradient Diffusion Method for Ceftolozane-Tazobactam Susceptibility Testing of Enterobacteriaceae and Pseudomonas aeruginosa.Journal of clinical microbiology · 2018
Article
Where Did They Come from-Multi-Drug Resistant PathogenicAntibiotics (Basel, Switzerland) · 2018
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Louie Mar GangcuangcoDepartment of Internal Medicine, Yale New Haven Health-Bridgeport Hospital, Bridgeport, CT, USA.ORCID 0000-0002-6714-9294

Patricia ClarkDepartment of Microbiology, Yale New Haven Health-Bridgeport Hospital, Bridgeport, CT, USA.

Cynthia StewartDepartment of Microbiology, Yale New Haven Health-Bridgeport Hospital, Bridgeport, CT, USA.

Goran MiljkovicDepartment of Internal Medicine, Yale New Haven Health-Bridgeport Hospital, Bridgeport, CT, USA; Internal Medicine and Infectious Disease Associates P.C., Stratford, CT, USA.

Zane K SaulDepartment of Internal Medicine, Yale New Haven Health-Bridgeport Hospital, Bridgeport, CT, USA; Internal Medicine and Infectious Disease Associates P.C., Stratford, CT, USA.

Bridgeport Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ceftazidime-avibactam and ceftolozane-tazobactam are new antimicrobials with activity against multidrug-resistant

Identifiers

PMID27818808

DOI10.1155/2016/1520404

PMCPMC5080512

OpenAlexW2530812453

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.